🏢 What Company Is Twist Bioscience?

Twist Bioscience (TWST) is a synthetic biology company that manufactures silicon-based synthetic DNA. Headquartered in California, USA, it leverages its proprietary silicon platform to mass-produce synthetic genes and DNA libraries, while also providing next-generation sequencing (NGS) tools, antibody discovery, and DNA data storage technologies.

The core business is manufacturing synthetic genes and gene libraries at low cost and high volume through its proprietary silicon platform. It additionally offers NGS tools, antibody discovery services, and long-term DNA data storage technology, and is growing rapidly in the synthetic biology and genomic tools space.

💰 How Does Twist Bioscience Make Money?

Recent revenue has continued to grow strongly, led by synthetic genes and genomic tools, with its silicon-based platform providing low-cost, high-volume production as a competitive edge. NGS tools and antibody discovery services diversify revenue, while long-term DNA data storage technology adds new growth opportunities. The company is pursuing a transition to profitability through expanded production capacity and improved cost efficiency, with revenue growth and margin improvement shaping the earnings trajectory.

📐 Twist Bioscience Market Cap and Company Size

Market cap stands at $5.7B, with 979명 employees.

As a fast-growing company in the synthetic biology and genomic tools space, it is positioned alongside genomic tool peers such as ILMN (Illumina), PACB (Pacific Biosciences), and TXG (10x Genomics). Its differentiated silicon-based synthetic DNA manufacturing technology and low-cost, high-volume production are key strengths, as it pursues revenue growth and a transition to profitability.

📈 Twist Bioscience Outlook and Stock Price Trends

Growing demand for synthetic biology and genomics research, along with the expansion of new applications such as antibody discovery and DNA data storage, are the key medium- to long-term growth drivers. Silicon-based low-cost, high-volume production provides differentiated competitive advantage, while expanded production capacity and improved cost efficiency support the transition to profitability. On the other hand, over the near term, the pace of profitability transition, the cost structure, any slowdown in research and biotech budgets, intensifying competition, and the commercialization speed of new applications could act as potential sources of volatility.

• Synthetic biology and genomics demand
• Expansion of antibody discovery and DNA data storage
• Improvements in production capacity and cost efficiency

⚔️ Twist Bioscience Core Competitive Strengths and Risks

Differentiated silicon-based synthetic DNA manufacturing technology and a high growth rate are key strengths, while the transition to profitability, a slowdown in research and biotech budgets, and intensifying competition are the core risks.

🔄 Twist Bioscience Competitors and Related (Beneficiary) Stocks

Directly comparable names in the genomic tools and synthetic biology space include ILMN (Illumina), PACB (Pacific Biosciences), and TXG (10x Genomics). Related names grouped under the life sciences tools theme include analytical equipment maker A (Agilent) and life sciences tools company TMO (Thermo Fisher), which share exposure to research and biotech demand.

✅ Investor Checkpoints for Twist Bioscience

Key checkpoints for Twist Bioscience investors. Revenue growth in synthetic genes and genomic tools, the profitability transition, commercialization of new applications, and the research and biotech budget environment are the key short- and medium-term variables.

The pace of the transition to profitability during this growth-investment stage is the core risk. Demand could contract if research and biotech budgets slow, and intensifying competition in the genomic tools and synthetic biology space, along with uncertainty around the commercialization speed of new applications, could also act as drivers of earnings volatility.

Twist Bioscience is a high-growth synthetic biology company with differentiated silicon-based synthetic DNA manufacturing technology, where low-cost, high-volume production and application diversification are key strengths. However, as a growth stock facing the profitability transition and competitive pressures, dollar-cost averaging and a long-term perspective are recommended.